For the quarter ending 2026-03-31, TOIIW made $147,441K in revenue. -$2,492K in net income. Net profit margin of -1.69%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total operating revenue | 147,441 | 118,180* | 136,564 | 119,802 |
| Direct costs-Health Care Patient Service | 53,383 | 46,919* | 54,572 | 51,150 |
| Direct costs-Dispensary Revenue | - | - | 63,072 | 51,086 |
| Direct costs-Health Care Specialty Pharmacy | 70,743 | 49,320* | - | - |
| Direct costs-Clinical Research Trials And Other Revenue | 0 | 137* | 0 | 65 |
| Selling, general and administrative expense | 28,212 | 27,337* | 25,251 | 26,907 |
| Depreciation and amortization | 1,616 | 1,652* | 1,723 | 1,805 |
| Total operating expenses | 153,954 | 125,364* | 144,618 | 131,013 |
| Loss from operations | -6,513 | -7,184* | -8,054 | -11,211 |
| Interest expense, net | 1,934 | 5,591* | 1,920 | 1,870 |
| Change in fair value of derivative warrant liabilities | -168 | -57* | 150 | 53 |
| Change in fair value of conversion option derivative liabilities | 4,996 | 2,740* | -5,977 | -3,987 |
| Other, net | 791 | -292* | -403 | -19 |
| Total other non-operating expense (income) | 4,021 | -3,085* | -8,450 | -5,929 |
| Loss before provision for income taxes | -2,492 | -10,270* | -16,504 | -17,140 |
| Income taxes | 0 | 66* | 0 | -131 |
| Net loss | -2,492 | -10,336 | -16,504 | -17,009 |
| Basic EPS | -0.02 | -0.12 | -0.14 | -0.15 |
| Diluted EPS | -0.02 | -0.12 | -0.14 | -0.15 |
| Basic Average Shares | 101,801,609 | 86,489,681 | 97,474,797 | 93,203,665 |
| Diluted Average Shares | 101,801,609 | 86,489,681 | 97,474,797 | 93,203,665 |
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)